Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

Treatment with Scemblix was shown to improve response rates in patients with newly diagnosed Philadelphia chromosome-positive ...

In 2020, leukemia (cancer of the blood) accounted for approximately 2.5 per cent of all new cancer cases and 3.1 per cent of deaths globally. Of these, chronic myeloid leukemia (CML) is a subtype that ...

Researchers sought to determine whether combination decitabine, venetoclax, and ponatinib would be effective in patients with accelerated phase CML.

Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.

Researchers sought to determine whether a low dose of bosutinib followed by escalation would be effective for patients with CML.

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% in order to be cost-effective compared with bendamustine-rituximab (R ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an ...

The World Health Organization has defined chronic disease as non-communicable diseases enduring for long durations (five-year ...

Scemblix (asciminib) is a new first-line option for adults with newly diagnosed Philadelphia chromosome-positive chronic ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...

Scemblix was granted accelerated approval by the FDA for the treatment of certain patients newly diagnosed with chronic ...